Rifaximin for Preventing Progression and Complications in Patients With Decompensated Liver Cirrhosis

NARecruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

August 18, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Decompensated Cirrhosis

Interventions

DRUG

Low-dose of Rifaximin

The patients in group B were given rifaximin with the dose of 600mg/d (600mg, qd) for 24 weeks

DRUG

Conventional dose of Rifaximin

the patients in group C were delivered 1200mg/d (600mg, bid) for 24 weeks

Trial Locations (1)

RECRUITING

Shanghai East Hospital, Shanghai

All Listed Sponsors

lead

Xin Zeng

OTHER